Market Overview

UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Related GHDX
Genomic Health Cancer Tests Strong, Operating Expenses a Woe
Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report?

Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.

Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."

Genomic Health closed at $36.15 on Monday.

Latest Ratings for GHDX

Aug 2017Canaccord GenuityMaintainsBuy
May 2017Raymond JamesDowngradesOutperformMarket Perform
Jan 2017Deutsche BankInitiates Coverage OnHold

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (GHDX)

View Comments and Join the Discussion!